Cancer Risk After Cyclophosphamide Treatment in Idiopathic Membranous Nephropathy

Clinical Journal of the American Society of Nephrology - United States
doi 10.2215/cjn.08880813
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Nephrology (ASN)

Related search

Controversies in the Treatment of Idiopathic Membranous Nephropathy

Nature Reviews Nephrology
Nephrology
2009English

Variation of Peripheral Th17/Treg Imbalance in Patients With Idiopathic Membranous Nephropathy After Cyclosporin a Treatment: A Prognostic Marker of Idiopathic Membranous Nephropathy

Biomedical Journal of Scientific & Technical Research
2018English

Effectiveness and Safety of Cyclophosphamide or Tacrolimus Therapy for Idiopathic Membranous Nephropathy

Renal Failure
MedicineNephrologyCritical CareIntensive Care Medicine
2019English

Risk HLA-DQA1 and PLA2R1 Alleles in Idiopathic Membranous Nephropathy

New England Journal of Medicine
Medicine
2011English

Chapter 7: Idiopathic Membranous Nephropathy

Kidney International Supplements
Nephrology
2012English

Comparison of Prognostic, Clinical, and Renal Histopathological Characteristics of Overlapping Idiopathic Membranous Nephropathy and IgA Nephropathy Versus Idiopathic Membranous Nephropathy

Scientific Reports
Multidisciplinary
2017English

Evaluating Tacrolimus Treatment in Idiopathic Membranous Nephropathy in a Cohort of 408 Patients

BMC Nephrology
Nephrology
2017English

Non-Ischemic Cardiomyopathy After Rituximab Treatment for Membranous Nephropathy

Journal of Renal Injury Prevention
UrologyNephrology
2016English

Idiopathic Membranous Nephropathy and IgG4: An Interesting Relationship

Clinical Nephrology
MedicineNephrology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy